NCT05254184View on ClinicalTrials.gov

KRAS-Targeted Vaccine With Nivolumab and Ipilimumab for Patients With NSCLC

PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

April 1, 2027

Study Completion Date

April 1, 2027

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Pooled Mutant KRAS-Targeted Long Peptide Vaccine 0.3mg each; 1.8mg total peptides

administering the KRAS peptide vaccine with poly-ICLC adjuvant in combination with nivolumab and ipilimumab

Trial Locations (1)

21287

RECRUITING

Johns Hopkins University, Baltimore

All Listed Sponsors
lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER